Literature DB >> 2459577

Serotonergic status in human blood.

J Ortiz1, F Artigas, E Gelpí.   

Abstract

Preliminary data on the existence of a plasma pool of serotonin (5HT) in human blood has been confirmed in a descriptive study of two distinctive pools of 5HT (plasma and platelet), and its metabolite 5-hydroxyindoleacetic acid (5HIAA), in the blood of 175 healthy individuals. Plasma 5HT (0.93 +/- 0.67 ng/mL, X +/- S.D.) shows a significant but low correlation with platelet 5HT (711 +/- 319 ng/10(9) platelets) (r=0.29, p less than 0.001). Diastolic blood pressure correlated significantly with plasma 5HT (r=0.51, p less than 0.05) and whole blood 5HT (r=0.52, p less than 0.05) in older individuals (50-65 years) but not in the whole group (r=0.052, n.s.). Differences between sexes include plasma 5HT, whole blood 5HT (both higher in women) and plasma 5HIAA (lower in women) and may reflect a differential whole body 5HT function. The effect of meal consumption and a peripheral 5HT synthesis inhibitor (carbidopa) in four human subjects has also been tested. Carbidopa (0.7 mg/kg) significantly lowers the plasma pool of 5HT (mean change -33%) 2 hr. after administration, while platelet 5HT is unchanged. These data support the existence of a human plasma 5HT pool, with a rapid turnover, different from the 5HT in platelets (slow turnover, reserve pool). Both may be useful in evaluating different aspects of 5HT-mediated pathologies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459577     DOI: 10.1016/0024-3205(88)90543-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  24 in total

1.  Plasma serotonin.

Authors:  G M Van Kempen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-09       Impact factor: 10.154

2.  Shape change of human blood platelets: reliable and fast detection by quasi-elastic light scattering.

Authors:  E Spurej; O Glatter; G Pfeiler
Journal:  Experientia       Date:  1992-01-15

3.  Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo.

Authors:  Brian J Mickey; Francesca Ducci; Colin A Hodgkinson; Scott A Langenecker; David Goldman; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

4.  Age-related changes in the serotonin 2A receptor in the hypoglossal nucleus of male and female rats.

Authors:  Benjamin R Seebart; Ryan T Stoffel; Mary Behan
Journal:  Respir Physiol Neurobiol       Date:  2007-02-14       Impact factor: 1.931

5.  Serotoninergic status in patients with hereditary vascular retinopathy syndrome.

Authors:  C W Storimans; D Fekkes; A van Dalen; E D Bleeker-Wagemakers; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

6.  5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate.

Authors:  Dustin W Wooten; Ansel T Hillmer; Jeffrey M Moirano; Dana L Tudorascu; Elizabeth O Ahlers; Maxim S Slesarev; Todd E Barnhart; Jogeshwar Mukherjee; Mary L Schneider; Bradley T Christian
Journal:  Neuroimage       Date:  2013-03-26       Impact factor: 6.556

Review 7.  Interactions between age, sex, and hormones in experimental ischemic stroke.

Authors:  Fudong Liu; Louise D McCullough
Journal:  Neurochem Int       Date:  2012-10-13       Impact factor: 3.921

8.  Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine.

Authors:  J Ortiz; F Artigas
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

9.  Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.

Authors:  Ana Belen Lopez-Rodriguez; Alvaro Llorente-Berzal; Luis M Garcia-Segura; Maria-Paz Viveros
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Gender moderates the association between 5-HTTLPR and decision-making under ambiguity but not under risk.

Authors:  Scott F Stoltenberg; Joanna M Vandever
Journal:  Neuropharmacology       Date:  2009-09-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.